Avatrombopag
Thrombocytopenia
Second Affiliated Hospital of Guangzhou Medical UniversitySmall moleculePhase 4 / ApprovedActive
BB
70/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 57/ 100
- Competitive Position
- 89/ 100
Competitive context
18 Active assets in the Thrombocytopenia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Recombinant Human Thrombopoietin Sun Yat-sen University | Phase 4 | BBB |
sb-497115-gr Institute of Hematology & Blood Diseases Hospital, China | Phase 4 | BB |
FILGRASTIM OHSU Knight Cancer Institute | Phase 2 | BB |
Hetrombopag Sun Yat-sen University | Phase 3 | BB |
Cytosin-Arabinosid OHSU Knight Cancer Institute | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Avatrombopag is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →